A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease

Trial Profile

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs NPT 088 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Proclara Biosciences
  • Most Recent Events

    • 05 Sep 2017 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
    • 05 Sep 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jul 2018.
    • 17 Jul 2017 According to a Proclara Biosciences media release, company expects to release topline efficacy data in the summer of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top